Medication Monitor



Generic Name (Trade Name—Company)
Notes
April 28, 2017

Midostaurin

(Rydapt—Novartis)
New agent approved for newly diagnosed acute myeloid leukemia

FDA approved midostaurin to treat adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive (FLT3+), as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.

The agency also approved a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe Technologies), for use with midostaurin to test patients with AML for the FLT3 mutation.

Approval was based on a randomized, double-blind, placebo-controlled trial in 717 patients with previously untreated FLT3+ AML. This trial randomized patients to either placebo or midostaurin 50 mg orally twice daily on days 8–21 of each cycle of induction and consolidation chemotherapy, followed by continuous daily midostaurin for up to 12 cycles. The trial demonstrated a statistically significant improvement in overall survival (OS) for patients receiving midostaurin compared with those in the placebo-containing arm (HR 0.77, P = 0.016).

Common adverse reactions, occurring in at least 20% of patients, included febrile neutropenia, nausea, mucositis, vomiting, headache, petechiae, musculoskeletal pain, epistaxis, device-related infection, hyperglycemia, and upper respiratory tract infection. The most frequent serious adverse reaction was febrile neutropenia, occurring in 16% of patients on both arms.

FDA also approved midostaurin to treat adults with aggressive systemic mastocytosis (SM), SM with associated hematological neoplasm, or mast cell leukemia. Approval was based on response rate and duration in a single-arm, open-label study of midostaurin 100 mg orally twice daily. With six cycles of midostaurin, the rates of confirmed complete remission (CR) plus incomplete remission (ICR) by modified Valent criteria were 38% for ASM and 16% for SM-AHN. One patient (5%) with mast cell leukemia achieved a CR. The most common adverse reactions included nausea, vomiting, diarrhea, edema, musculoskeletal pain, abdominal pain, fatigue, upper respiratory tract infection, fever, headache, and dyspnea.

The recommended dose of midostaurin in AML is 50 mg twice daily with food on days 8–21 of each cycle of induction and consolidation chemotherapy followed by 50 mg with food as a single agent for up to 12 months. The recommended dose for treatment of adults with aggressive systemic mastocytosis (SM), SM with associated hematological neoplasm, or mast cell leukemia is 100 mg twice daily with food.